ElectroCore posted record third-quarter 2025 revenue of $8.7 million, up 33% year over year, and lifted full-year guidance to $31.5–$32.5 million. Growth was led by prescription neuromodulation devices in the U.S. Department of Veterans Affairs, with 195 VA facilities purchasing gammaCore, up from 166 a year ago, and by the Quell Fibromyalgia device, added through the NeuroMetrix acquisition. The company’s consumer-facing TruVaga line also hit a quarterly high, contributing to a 86% gross margin and year-to-date sales of $22.8 million, up 26%. Despite top-line momentum, the net loss widened to $3.4 million, driven by higher selling expenses and acquisition-related costs tied to a contingent value right and convertible debt. Management targets the first positive adjusted EBITDA in the second half of 2026, contingent on reaching $12 million in quarterly revenue.
The strategic question is whether a VA-first, hybrid Rx-plus-wellness model can scale bioelectronic medicine into a sustainable, payer-accepted category before financing constraints force a reset. ElectroCore’s unit economics look attractive, but the path from $8.7 million to $12 million per quarter will require more than procurement wins. It will demand payer-convincing real-world evidence in chronic pain and migraine, disciplined channel management between prescription and consumer offerings, and a tighter operating envelope as liabilities rise and equity turns negative.
Why this matters now is twofold. For patients and HCPs, the VA’s uptake validates non-invasive neuromodulation as a credible alternative to pharmacotherapy in hard-to-treat pain syndromes, with potential downstream benefits on opioid avoidance and polypharmacy. For payers, the question is budget impact and adherence: can devices like gammaCore and Quell deliver sustained reductions in acute care utilization and medication spend in real-world settings, and can an app-enabled workflow maintain long-term adherence outside integrated systems like the VA? For competitors in neuromodulation and digital therapeutics 2.0, the VA beachhead demonstrates a viable commercialization sequence at a time when commercial plans remain cautious, and prior digital health models faltered on reimbursement.
This update also aligns with a broader industry trend. Bioelectronic medicine is moving from concept to commercial traction through targeted channels where clinical oversight and centralized procurement accelerate adoption. Asset-light M&A structures, including CVRs, are being used to bolt on cleared devices and revenue lines without committing to ample cash outlays. Meanwhile, consumer wellness adjacencies offer cash-generative upside but carry brand architecture risk if they blur clinical positioning or trigger payer skepticism. The financing backdrop remains unforgiving; reliance on convertible debt and contingent obligations raises the stakes on execution, even as high gross margins suggest operating leverage is within reach if sales productivity compounds.
For Commercial and Medical Affairs leaders, two levers will likely determine whether ElectroCore’s guidance raise is a waypoint to scale or a ceiling. First, evidence: head-to-heads versus standard of care, VA-derived outcomes studies, and HEOR packages tailored for commercial plans will be essential to move beyond government channels. Second, channel strategy: preserving the clinical premium of prescription neuromodulation while harnessing consumer demand for wellness devices requires segmentation, pricing discipline, and clear value narratives to HCPs and payers.
If the company can turn VA validation into broader payer coverage and maintain DTC momentum without cannibalizing its Rx brands, bioelectronic medicine could claim a durable spot in mainstream pain care. The following 12–18 months will show whether this is a niche VA success or the template for scaling neuromodulation commercially. The sharper question for the sector: will a partnership with a larger medtech or pharma be the catalyst that converts promising unit economics into market-wide reimbursement before the capital clock runs out?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
